We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

70 hedge funds and large institutions have $116M invested in Invesco Biotechnology & Genome ETF in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $113M → $116M (+$2.43M)

0.52% less ownership

Funds ownership: 29.56% → 29.04% (-0.52%)

5% less funds holding

Funds holding: 74 → 70 (-4)

10% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 20

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
70
Holders Change
-4
Holders Change %
-5.41%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
18
Reduced
20
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BWP
Baldwin Wealth Partners
Massachusetts
+$1.49M
2
NDSI
Newman Dignan & Sheerar Inc
Rhode Island
+$1.28M
3
MCM
Murphy Capital Management
New Jersey
+$233K
4
GT
Glenmede Trust
Pennsylvania
+$165K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$154K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.62M
2
VKH
Virtu KCG Holdings
New York
-$1.58M
3
Goldman Sachs
Goldman Sachs
New York
-$1.18M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$823K
5
Bank of America
Bank of America
North Carolina
-$617K
Name Holding Trade Value Shares
Change 		Change in
Stake
AP
51
Advisors Preferred
Maryland
$46.8K -$28.5K -633 -38%
BC
52
Bartlett & Co
Ohio
$46K – – –
WA
53
WFG Advisors
Texas
$43K -$75.5K -1,675 -64%
PAG
54
Private Advisor Group
New Jersey
$42K +$41.3K +916 New
1IC
55
1919 Investment Counsel
Maryland
$37K – – –
FANJ
56
Financial Architects (New Jersey)
New Jersey
$35K – – –
PTC
57
Private Trust Company
Ohio
$32K – – –
LFR
58
Lehman Financial Resources
Pennsylvania
$28K – – –
RFA
59
Reilly Financial Advisors
California
$28K – – –
MCM
60
Manchester Capital Management
Vermont
$25K – – –
MAS
61
Madden Advisory Services
Florida
$18K – – –
NES
62
New England Securities
New York
$17K – – –
BCM
63
Blume Capital Management
California
$16K – – –
PSI
64
Pinnacle Summer Investments
Virginia
$16K – – –
DADC
65
D.A. Davidson & Co
Montana
$12K – – –
Creative Planning
66
Creative Planning
Kansas
$9K -$45K -1,000 -83%
NFG
67
Next Financial Group
Texas
$9K +$9.01K +200 New
BCMIO
68
Beacon Capital Management Inc (Ohio)
Ohio
$7K – – –
AA
69
Apriem Advisors
California
$5K – – –
Northwestern Mutual Wealth Management
70
Northwestern Mutual Wealth Management
Wisconsin
$5K +$4.5K +100 New
BFEC
71
Benjamin F. Edwards & Company
Missouri
$2K – – –
VKH
72
Virtu KCG Holdings
New York
– -$1.58M -36,178 Closed
Jane Street
73
Jane Street
New York
– -$237K -5,418 Closed
WA
74
WBH Advisory
Maryland
– -$225K -5,154 Closed
MC
75
Moors & Cabot
Massachusetts
– -$219K -5,014 Closed
1 2
3
4

PBE Hedge Fund Activity: Q3 2014 in Review

70 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2014, worth a combined $116M — up 2.1% from $113M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PBE and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 18 added.

The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.49M. The largest seller was Morgan Stanley, cutting an estimated $1.62M.

  • 70 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2014, down from 74 in Q2 2014.
  • Funds reported $116M of Invesco Biotechnology & Genome ETF stock for Q3 2014, up 2.1% quarter-over-quarter.
  • 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2014 and 11 closed out, a net change of -4 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q3 2014 was Baldwin Wealth Partners, an estimated $1.49M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q3 2014 was Morgan Stanley, an estimated $1.62M sold.

Based on aggregated 13F filings for Q3 2014.